Clinical trial
R115777 to Treat Children With Neurofibromatosis Type 1 and Progressive…
NCT00021541 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00021541 |
|---|---|
| Title | R115777 to Treat Children With Neurofibromatosis Type 1 and Progressive Plexiform Neurofibromas |
| Official title | A Phase II Randomized, Cross-Over, Double-Blinded, Placebo-Controlled Trial of the Farnesyltransferase Inhibitor R115777 in Pediatric Patients With Neurofibromatosis Type I and Progressive Plexiform Neurofibromas |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Neurofibroma, Plexiform, Neurofibromatosis Type I |
| Intervention type | Drug, Other |
| Interventions | tipifarnib, placebo |
| Enrollment | 62 |
| Start date | Jul 17, 2001 |
| Primary completion | Feb 19, 2009 |
| Completion | Feb 19, 2009 |
| First posted | Jul 23, 2001 |
| Last update posted | Apr 17, 2018 |
| Countries | Germany, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: